Robert O’Connell, MBA, has served as senior director of pharmacology focusing on gastrointestinal diseases at Inotiv since May of 2021. In this position he manages four principal investigators, support staff, and coordinators at Inotiv’s Boulder location. While these groups oversee studies from all disease areas, O’Connell develops efficacy studies for novel therapeutics in preclinical models of inflammatory bowel disease and general inflammation. He remains a field leader in the study of treatments for IBD.
Before joining Inotiv, O’Connell developed a strong scientific career in preclinical models of disease. He started managing efficacy studies in the department of pharmacology and toxicology at Virginia Commonwealth University, then moved to HistoTox Labs to develop his immunohistochemistry skills. In 2013, he moved to Bolder BioPATH as an associate scientist, where he started working for clients on inflammatory bowel disease. His excellence in the field soon earned him a place as a principal investigator in 2015. In 2019 he became a vice president of research until joining Inotiv. He brings Inotiv a talented and high-achieving researcher in the gastrointestinal space, with a track record of research success.